Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2018
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2018
SUMMARY
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 9 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Respiratory which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Gastric Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Epithelial Ovarian Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Pancreatic Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Metastasis, Carcinoid Tumor, Colorectal Cancer, Endometrial Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Idiopathic Pulmonary Fibrosis, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Rhabdomyosarcoma, Oral Cavity (Mouth) Cancer, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Peritoneal Cancer, Pheochromocytoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Squamous Cell Carcinoma, Thrombosis, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 9 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Respiratory which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Gastric Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Epithelial Ovarian Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Pancreatic Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Metastasis, Carcinoid Tumor, Colorectal Cancer, Endometrial Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Idiopathic Pulmonary Fibrosis, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Rhabdomyosarcoma, Oral Cavity (Mouth) Cancer, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Peritoneal Cancer, Pheochromocytoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Squamous Cell Carcinoma, Thrombosis, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
Incyte Corp
Les Laboratoires Servier SAS
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Takeda Pharmaceutical Co Ltd
Tolero Pharmaceuticals Inc
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bemcentinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-30138 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit Axl Tyrosine kinase for Non-Small Cell Lung Cancer and Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gilteritinib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-81776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-916562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-49076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-391 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MERTK and AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 02, 2018: BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA in advanced NSCLC at SITC
Oct 22, 2018: BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor Bemcentinib presented at ESMO
Oct 22, 2018: Exelixis announces results from the dose-escalation stage of the phase 1b COSMIC-021 study of Cabozantinib in combination with Atezolizumab in previously untreated advanced renal cell carcinoma
Oct 21, 2018: Mirati Therapeutics announces updated data from ongoing clinical trial of single agent Sitravatinib at the 2018 ESMO Congress
Oct 20, 2018: Exelixis announces results from two analyses evaluating effect of PD-L1expression or prior treatment with checkpoint inhibitors on efficacy of Cabozantinib in patients with advanced renal cell carcinoma
Oct 19, 2018: Daiichi Sankyo initiates phase 1 study of AXL inhibitor DS-1205 in patients with EGFR-mutated metastatic non-small cell lung cancer
Oct 15, 2018: Mirati therapeutics to provide updated Sitravatinib clinical data at the European Society for Medical Oncology (ESMO) 2018 congress and conduct investor call
Oct 12, 2018: Ipsen to present data on Cabometyx at ESMO 2018
Oct 09, 2018: BerGenBio to present interim phase II clinical, preclinical and biomarker data with selective AXL inhibitor Bemcentinib at ESMO
Oct 08, 2018: Cabozantinib to be featured in 13 presentations at ESMO 2018 Congress
Oct 08, 2018: BerGenBio doses first patient in second part of BGBC008 trial
Oct 08, 2018: Exelixis initiates phase 3 pivotal trial (COSMIC-311) of Cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy
Sep 28, 2018: Invivoscribe receives approval in Japan for its LeukoStrat CDx FLT3 Mutation Assay for the assessment of acute myeloid leukemia (AML) patients treated with Xospata (gilteritinib fumarate)
Sep 25, 2018: BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes
Sep 21, 2018: Astellas announces approval in Japan for XOSPATA 40 mg tablets for the treatment of FLT3mut+ Relapsed or Refractory AML
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
Incyte Corp
Les Laboratoires Servier SAS
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Takeda Pharmaceutical Co Ltd
Tolero Pharmaceuticals Inc
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bemcentinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-30138 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit Axl Tyrosine kinase for Non-Small Cell Lung Cancer and Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gilteritinib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-81776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-916562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-49076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-391 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MERTK and AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 02, 2018: BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA in advanced NSCLC at SITC
Oct 22, 2018: BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor Bemcentinib presented at ESMO
Oct 22, 2018: Exelixis announces results from the dose-escalation stage of the phase 1b COSMIC-021 study of Cabozantinib in combination with Atezolizumab in previously untreated advanced renal cell carcinoma
Oct 21, 2018: Mirati Therapeutics announces updated data from ongoing clinical trial of single agent Sitravatinib at the 2018 ESMO Congress
Oct 20, 2018: Exelixis announces results from two analyses evaluating effect of PD-L1expression or prior treatment with checkpoint inhibitors on efficacy of Cabozantinib in patients with advanced renal cell carcinoma
Oct 19, 2018: Daiichi Sankyo initiates phase 1 study of AXL inhibitor DS-1205 in patients with EGFR-mutated metastatic non-small cell lung cancer
Oct 15, 2018: Mirati therapeutics to provide updated Sitravatinib clinical data at the European Society for Medical Oncology (ESMO) 2018 congress and conduct investor call
Oct 12, 2018: Ipsen to present data on Cabometyx at ESMO 2018
Oct 09, 2018: BerGenBio to present interim phase II clinical, preclinical and biomarker data with selective AXL inhibitor Bemcentinib at ESMO
Oct 08, 2018: Cabozantinib to be featured in 13 presentations at ESMO 2018 Congress
Oct 08, 2018: BerGenBio doses first patient in second part of BGBC008 trial
Oct 08, 2018: Exelixis initiates phase 3 pivotal trial (COSMIC-311) of Cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy
Sep 28, 2018: Invivoscribe receives approval in Japan for its LeukoStrat CDx FLT3 Mutation Assay for the assessment of acute myeloid leukemia (AML) patients treated with Xospata (gilteritinib fumarate)
Sep 25, 2018: BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes
Sep 21, 2018: Astellas announces approval in Japan for XOSPATA 40 mg tablets for the treatment of FLT3mut+ Relapsed or Refractory AML
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by BerGenBio ASA, H2 2018
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018
Pipeline by Celldex Therapeutics Inc, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Exelixis Inc, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by F1 Oncology Inc, H2 2018
Pipeline by Genosco Inc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Les Laboratoires Servier SAS, H2 2018
Pipeline by Mirati Therapeutics Inc, H2 2018
Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Pipeline by Oribase Pharma, H2 2018
Pipeline by Qurient Co Ltd, H2 2018
Pipeline by Rigel Pharmaceuticals Inc, H2 2018
Pipeline by SignalChem Lifesciences Corp, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Tolero Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by BerGenBio ASA, H2 2018
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018
Pipeline by Celldex Therapeutics Inc, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Exelixis Inc, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by F1 Oncology Inc, H2 2018
Pipeline by Genosco Inc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Les Laboratoires Servier SAS, H2 2018
Pipeline by Mirati Therapeutics Inc, H2 2018
Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Pipeline by Oribase Pharma, H2 2018
Pipeline by Qurient Co Ltd, H2 2018
Pipeline by Rigel Pharmaceuticals Inc, H2 2018
Pipeline by SignalChem Lifesciences Corp, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Tolero Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
Incyte Corp
Les Laboratoires Servier SAS
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Takeda Pharmaceutical Co Ltd
Tolero Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
Incyte Corp
Les Laboratoires Servier SAS
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Takeda Pharmaceutical Co Ltd
Tolero Pharmaceuticals Inc
